Questions on the regulatory mechanisms of IL-1 signaling; the crosstalk network between different cells and between different intracellular signal transductions, by which IL-1 signaling and its regulation affect aspects of inflammation, immunity, metastasis, and drug resistance in BC microenvironment; and the usability of IL-1 signaling blockade in terms of clinical treatment in BC may lead us to discover a novel biomarker or effective therapeutic target. This evidence concerns the gene IL1A and breast cancer.